GSK (GSK) said Monday that the European Medicines Agency has accepted for review the marketing authorization application for its experimental drug, linerixibat, to treat cholestatic pruritus in patients with primary biliary cholangitis, a rare autoimmune liver condition.
The drugmaker said the submission is backed by a phase 3 trial that showed the drug significantly improved cholestatic pruritus and itching-related sleep disruption compared to placebo.
Linerixibat is not yet approved in any country, it added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.